Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: dermal

Currently viewing:

Administrative data

Endpoint:
sub-chronic toxicity: dermal
Type of information:
experimental study
Adequacy of study:
supporting study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Study meets basic scientific principles, specific focus on prostrate, no further endpoints examined, single dose group only

Data source

Referenceopen allclose all

Reference Type:
publication
Title:
Early Stages of the Pathogenesis of Rat Ventral Prostate Hyperplasia / Induced by Citral
Author:
Servadio C, Abramovici A, Sandbank U, Savion M, Rosen M
Year:
1986
Bibliographic source:
Eur. Urol. 12, 195-200
Reference Type:
other: Abstract for scientific meeting
Title:
Further observations on the citral-induced experimental model of benign prostatic hyperplasia (BPH) in the rat
Author:
Servadio C, Abramovici A
Year:
1986
Bibliographic source:
Urol. Res. 14, 172

Materials and methods

Principles of method if other than guideline:
Specific histological examination of prostates for induction of benign hyperplasia
GLP compliance:
not specified

Test material

Constituent 1
Reference substance name:
Citral
EC Number:
226-394-6
EC Name:
Citral
Cas Number:
5392-40-5
IUPAC Name:
3,7-dimethylocta-2,6-dienal
Constituent 2
Chemical structure
Reference substance name:
(Z)-3,7-dimethylocta-2,6-dienal
EC Number:
203-379-2
EC Name:
(Z)-3,7-dimethylocta-2,6-dienal
Cas Number:
106-26-3
Molecular formula:
C10H16O
IUPAC Name:
(2Z)-3,7-dimethylocta-2,6-dienal
Details on test material:
- Name of test material (as cited in study report): Citral

Test animals

Species:
rat
Strain:
Wistar
Sex:
male
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Age at study initiation: 6 weeks
- Weight at study initiation: 150 g
- Fasting period before study: none
- Diet: standard chow pellets ad libitum
- Water: ad libitum
- Special pretreatment: animals from groups II and V were subjected to bilateral surgical orchidectomy 24 hrs prior to start of citral treatment

ENVIRONMENTAL CONDITIONS: climatized environment
- Temperature (°C): not specified
- Humidity (%): not specified
- Photoperiod (hrs dark / hrs light): 12/12

Administration / exposure

Type of coverage:
open
Vehicle:
other: 70 % ethanol
Details on exposure:
Route of Administration: dermal
TEST SITE
- Area of exposure: shaved skin of the back
- % coverage: no data

TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 0.2 mL of a solution of citral dissolved in 70 % ethanol
- Concentration (if solution): not specified

VEHICLE
- Justification for use and choice of vehicle (if other than water): solubility

USE OF RESTRAINERS FOR PREVENTING INGESTION: no data
Analytical verification of doses or concentrations:
not specified
Duration of treatment / exposure:
10, 20, 30, 60, 90 days (intact rats)
10, 20, 30, 40, 50, 60 days (orchidectomized rats)
Frequency of treatment:
5 d/w
Doses / concentrations
Remarks:
Doses / Concentrations:
150 mg/kg bw/day
Basis:
nominal per unit body weight
No. of animals per sex per dose:
not specified (N=54 in total)
Control animals:
yes, concurrent vehicle
Details on study design:
Study groups:
I: citral treatment, intact rats
II: citral treatment, orchidectomized rats
III: untreated control
IV: vehicle control, intact rats
V: vehicle control, orchidectomized rats
Positive control:
no

Examinations

Sacrifice and pathology:
GROSS PATHOLOGY: Yes, only prostrate
prostrate weight and macroscopic examination

HISTOPATHOLOGY: Yes, only prostrate
microscopic examination

Results and discussion

Results of examinations

Details on results:
GROSS PATHOLOGY
Prostrate weight: progressive increase in citral-treated rats (group I) with duration of treatment visible after 10 days of treatment compared to untreated and vehicle control (III and IV); significant reduction in group II (citral-treated, castrated rats) within 10 days compared to untreated and vehicle control (III and IV); weights after 60 days of treatment: group I: 1.44 +- 0.24 g, III: 0.88 +- 0.10 g, IV: 0.92 +- 0.08 g

Macroscopic examination: enlarged ventral prostrate in group I, atrophic prostrate in group II, both compared to untreated control (III)


HISTOPATHOLOGY: NON-NEOPLASTIC
Group I: definite lesions already after 10 days of treatment, becoming progressively more pronounced with duration of treatment expanding over many lobules at time;
findings after 1 mo: enhanced epithelial hyperplasia, stromal elements less reactive
findings after 3 months: significant proliferation of the acini, cystic dilatation lined by atrophic flat cuboid cells; supporting stroma more prominent than in the normal prostrate, mild chronic inflammatory foci often seen, intraluminal secretion deeply eosinophilic and more viscous

Group II: castration prior to citral administration prevented benign prostratic hyperplasia
No data specified for Group V.

Target system / organ toxicity

Critical effects observed:
not specified

Applicant's summary and conclusion